Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AADI Aadi Bioscience	$1.90 +1.6%	$1.76	$1.21 ▼ $3.81	$46.92M	0.68	266,071 shs	82,732 shs
ACRX AcelRx Pharmaceuticals		$0.77	$0.43 ▼ $2.78	$14.58M	0.52	137,683 shs	243,500 shs
ATNM Actinium Pharmaceuticals	$1.61 -0.9%	$1.55	$1.03 ▼ $8.64	$50.23M	-0.27	505,241 shs	48,898 shs
OSTX OS Therapies	$1.85 +2.2%	$1.75	$1.12 ▼ $7.00	$51.98M	N/A	459,576 shs	134,781 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AADI Aadi Bioscience	0.00%	-7.80%	+7.39%	-0.53%	+18.13%
ACRX AcelRx Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
ATNM Actinium Pharmaceuticals	-1.82%	+10.96%	-1.82%	-10.50%	-78.02%
OSTX OS Therapies	+2.84%	-0.55%	+13.13%	+11.73%	+180,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AADI Aadi Bioscience	0.565 of 5 stars	1.0	0.0	0.0	0.0	1.1	2.5	1.3
ACRX AcelRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ATNM Actinium Pharmaceuticals	1.9576 of 5 stars	3.4	5.0	0.0	0.0	0.0	0.0	0.6
OSTX OS Therapies	2.525 of 5 stars	3.7	0.0	0.0	0.0	2.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AADI Aadi Bioscience	2.00	Hold	$1.67	-12.28% Downside
ACRX AcelRx Pharmaceuticals	0.00	N/A	N/A	N/A
ATNM Actinium Pharmaceuticals	2.75	Moderate Buy	$4.00	149.22% Upside
OSTX OS Therapies	3.40	Buy	$18.00	872.97% Upside

Current Analyst Ratings Breakdown

Latest ACRX, AADI, OSTX, and ATNM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/24/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/9/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
5/15/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/12/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/28/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/22/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/7/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/2/2025	OSTX OS Therapies	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
4/1/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
3/31/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AADI Aadi Bioscience	$25.07M	1.87	N/A	N/A	$4.29 per share	0.44
ACRX AcelRx Pharmaceuticals	$1.77M	0.00	N/A	N/A	$2.65 per share	0.00
ATNM Actinium Pharmaceuticals	$81K	618.14	N/A	N/A	$1.31 per share	1.23
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AADI Aadi Bioscience	-$65.76M	-$2.35	N/A	N/A	N/A	-246.06%	-71.87%	-57.28%	8/5/2025 (Estimated)
ACRX AcelRx Pharmaceuticals	$47.76M	-$2.23	N/A	N/A	N/A	N/A	-81.54%	-46.02%	N/A
ATNM Actinium Pharmaceuticals	-$48.82M	-$1.39	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
OSTX OS Therapies	-$7.79M	-$0.86	N/A	N/A	N/A	N/A	N/A	-569.57%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AADI Aadi Bioscience	N/A	N/A	N/A	N/A	N/A
ACRX AcelRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AADI Aadi Bioscience	N/A	4.89	4.54
ACRX AcelRx Pharmaceuticals	N/A	4.04	4.04
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
OSTX OS Therapies	N/A	0.76	0.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AADI Aadi Bioscience	52.08%
ACRX AcelRx Pharmaceuticals	19.79%
ATNM Actinium Pharmaceuticals	27.50%
OSTX OS Therapies	N/A

Insider Ownership

Company	Insider Ownership
AADI Aadi Bioscience	37.30%
ACRX AcelRx Pharmaceuticals	3.00%
ATNM Actinium Pharmaceuticals	6.00%
OSTX OS Therapies	13.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AADI Aadi Bioscience	40	24.70 million	15.49 million	Optionable
ACRX AcelRx Pharmaceuticals	19	16.95 million	16.44 million	Optionable
ATNM Actinium Pharmaceuticals	30	31.20 million	29.32 million	Optionable
OSTX OS Therapies	N/A	28.10 million	N/A	N/A

ACRX, AADI, OSTX, and ATNM Headlines

Recent News About These Companies

OS Therapies Stock Surges 12.4% After Positive FDA Feedback on OST-HER2

June 24 at 4:09 PM | msn.com

OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

June 24 at 7:40 AM | businesswire.com

OS Therapies Announces Warrant Exercise Inducement & Exchange Offer

June 23, 2025 | businesswire.com

OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

June 10, 2025 | prnewswire.com

OSTX OS Therapies Incorporated

June 1, 2025 | seekingalpha.com

Buy Rating for OS Therapies: Promising Developments and Strategic Positioning in Cancer Immunotherapy

May 21, 2025 | tipranks.com

OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

May 16, 2025 | businesswire.com

OS Therapies Launches Subsidiary To Commercialize Canine Osteosarcoma Treatment

May 16, 2025 | finanzen.atF

OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma

May 15, 2025 | finance.yahoo.com

OS Therapies Inc (NYSE:OSTX) Major Shareholder Shalom Auerbach Sells 82,000 Shares

May 10, 2025 | insidertrades.com

OS Therapies Inc sees $163,918 in stock sales by major shareholder

May 9, 2025 | investing.com

OS Therapies secures patent for cancer immunotherapy tech

May 8, 2025 | investing.com

Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies

May 2, 2025 | businesswire.com

OS Therapies granted FDA meeting for OST-HER2

April 22, 2025 | markets.businessinsider.com

OS Therapies FDA Meeting Request Granted

April 22, 2025 | businesswire.com

OS Therapies Inc (NYSE:OSTX) Major Shareholder Sells $67,516.20 in Stock

April 12, 2025 | insidertrades.com

OS Therapies Announces Positive Data From The Study Of OST-HER2 In Osteosarcoma In Dogs

April 12, 2025 | nasdaq.com

OS Therapies Inc: Shalom Auerbach sells $81,566 in common stock

April 11, 2025 | investing.com

OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans

April 10, 2025 | businesswire.com

OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans

April 10, 2025 | newsfilecorp.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRX, AADI, OSTX, and ATNM Company Descriptions

Aadi Bioscience NASDAQ:AADI

$1.90 +0.03 (+1.60%)

As of 06/26/2025

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

AcelRx Pharmaceuticals NASDAQ:ACRX

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.

Actinium Pharmaceuticals NYSE:ATNM

$1.60 -0.02 (-0.93%)

As of 11:53 AM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

OS Therapies NYSE:OSTX

$1.85 +0.04 (+2.21%)

As of 11:53 AM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time